EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial

Wenli Dai, Qiang Lv, Qingling Li, Lu Fu, Yawei Zhang, Yumin Zhang, Lijun Liu, Ryohei Tanigawa, Keisuke Kunitomi, Ryo Kamei, Hideki Suganami, Changsheng Ma

Journal of Atherosclerosis and Thrombosis · 2025

DOI: 10.5551/jat.64112 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2025. Verfasst von Wenli Dai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital, Capital Medical University. Hauptthemen laut MEDLINE: Benzoxazoles, PPAR alpha, Butyrates, Dyslipidemias. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazolesPPAR alphaButyratesDyslipidemiasHypolipidemic AgentsHumansMaleDouble-Blind MethodMiddle AgedFemaleChinaAdultTriglyceridesCholesterol, HDLTreatment OutcomeFenofibrateFollow-Up StudiesAgedPrognosisEast Asian People

Stichwörter der Autor:innen

Clinical trialDyslipidemiaPemafibrateSelective PPARα modulatorTriglyceride

Substanzen

(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidBenzoxazolesPPAR alphaButyratesTriglyceridesHypolipidemic AgentsPPARA protein, humanCholesterol, HDLFenofibrate

Autor:innen und Institutionen

  • Beijing Anzhen Hospital, Capital Medical University.
  • Chengdu Xinhua Hospital.
  • The First Affiliated Hospital of Harbin Medical University.
  • Pingxiang People's Hospital.
  • The Third Hospital of Changsha.
  • The First Hospital of Anhui University of Science and Technology.

Zitieren

APA

Dai, W., Lv, Q., Li, Q., Fu, L., Zhang, Y., Zhang, Y., Liu, L., Tanigawa, R., Kunitomi, K., Kamei, R., Suganami, H., & Ma, C. (2025). Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.64112

Vancouver

Dai W, Lv Q, Li Q, Fu L, Zhang Y, Zhang Y, et al. Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial. Journal of Atherosclerosis and Thrombosis. 2025. doi:10.5551/jat.64112

BibTeX
@article{Dai2025,
  author = {Dai, Wenli and Lv, Qiang and Li, Qingling and Fu, Lu and Zhang, Yawei and Zhang, Yumin and Liu, Lijun and Tanigawa, Ryohei and Kunitomi, Keisuke and Kamei, Ryo and Suganami, Hideki and Ma, Changsheng},
  title = {Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2025},
  doi = {10.5551/jat.64112}
}
Kostenlos starten →